Cost-Effectiveness of Masked Hypertension Screening and Treatment in US Adults With Suspected Masked Hypertension: A Simulation Study

Matthew B. Green,1,a Daichi Shimbo,1,a Joseph E. Schwartz,1,2 Adam P. Bress,3 Jordan B. King,3 Paul Muntner,4 James P. Sheppard,5 Richard J. McManus,5 Ciaran N. Kohli-Lynch,6 Yiyi Zhang,1 Steven Shea,1 Andrew E. Moran,1 and Brandon K. Bellows1,a

BACKGROUND
Recent US blood pressure (BP) guidelines recommend using ambulatory BP monitoring (ABPM) or home BP monitoring (HBPM) to screen adults for masked hypertension. However, limited evidence exists of the expected long-term effects of screening for and treating masked hypertension.

METHODS
We estimated the lifetime health and economic outcomes of screening for and treating masked hypertension using the Cardiovascular Disease (CVD) Policy Model, a validated microsimulation model. We simulated a cohort of 100,000 US adults aged ≥20 years with suspected masked hypertension (i.e., office BP 120–129/<80 mm Hg, not taking antihypertensive medications, without CVD history). We compared usual care only (i.e., no screening), usual care plus ABPM, and usual care plus HBPM. We projected total direct healthcare costs (2021 USD), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios. Future costs and QALYs were discounted 3% annually. Secondary outcomes included CVD events and serious adverse events.

RESULTS
Relative to usual care, adding masked hypertension screening and treatment with ABPM and HBPM was projected to prevent 14.3 and 20.5 CVD events per 100,000 person-years, increase the proportion experiencing any treatment-related serious adverse events by 2.7 and 5.1 percentage points, and increase mean total costs by $1,076 and $1,046, respectively. Compared with usual care, adding ABPM was estimated to cost $85,164/QALY gained. HBPM resulted in lower QALYs than usual care due to increased treatment-related adverse events and pill-taking disutility.

CONCLUSIONS
The results from our simulation study suggest screening with ABPM and treating masked hypertension is cost-effective in US adults with suspected masked hypertension.

GRAPHICAL ABSTRACT

Keywords: ambulatory blood pressure monitoring; blood pressure; cost-effectiveness; home blood pressure monitoring; hypertension; masked hypertension.

https://doi.org/10.1093/ajh/hpac071
Masked hypertension is defined as having high out-of-office blood pressure (BP) without high office BP among individuals not taking antihypertensive medication. It is estimated that 17.1 million adults in the United States have masked hypertension. The risk of incident cardiovascular disease (CVD) and mortality associated with masked hypertension is similar to that of sustained hypertension (both office and out-of-office BP ≥130/80 mm Hg), nearly 2 times that of sustained normotension (both office BP and out-of-office BP <130/80 mm Hg). Using office BP measurements alone will not identify individuals with masked hypertension.

Several BP guidelines recommend screening for masked hypertension among adults without high office BP and treatment for those diagnosed with masked hypertension. The 2017 American College of Cardiology/American Heart Association (ACC/AHA) BP guideline stated it is reasonable to screen for masked hypertension in adults not taking an antihypertensive medication and with office BP readings of 120–129 mm Hg/75–79 mm Hg (Class IIa recommendation). Treatment with antihypertensive medication is associated with a significant reduction in CVD risk in those with high office BP, but there are currently no randomized clinical trials that have evaluated the effect of treating masked hypertension on CVD outcomes. Despite this, the 2017 ACC/AHA BP guideline stated that initiation of antihypertensive medication for those with masked hypertension is reasonable based on current observational study evidence (Class IIa recommendation).

Out-of-office BP can be measured using ambulatory BP monitoring (ABPM) or home BP monitoring (HBPM). ABPM automatically measures BP, typically every 20–30 minutes, over a 24-hour period, including during the sleep period. HBPM requires an individual to measure their BP in the morning and at night over a minimum of 3 days. ABPM is often considered the reference standard for hypertension diagnosis, but BP guidelines also support the use of HBPM, which is less expensive, and more readily accessible than ABPM.

Despite recommendations from BP guidelines to screen for masked hypertension using out-of-office BP monitoring, the expected long-term impact of screening for and treating masked hypertension on the risk of incident CVD events, risk of medication-related serious adverse events, and healthcare costs are currently unknown. This study seeks to estimate the lifetime cost-effectiveness of masked hypertension screening and treatment compared with usual care.

METHODS

Model overview

We used a microsimulation version of the CVD Policy Model, an established computer simulation of coronary heart disease (CHD) and stroke incidence and prevalence in US adults. In the simulation, individuals started with no history of CVD and each year were at risk of experiencing CHD, stroke, both CHD and stroke, and dying from CVD or non-CVD-related causes (Supplementary Figure S1 online). Individuals were simulated until age 89 years or death.

The simulation model and key inputs used to conduct this research are available upon reasonable request and approval by the model team. Interested researchers can submit a research proposal and collaboration plan to Dr. Bellows and will be required to sign a Creative Commons agreement.

Population

The model was populated with individuals from National Health and Nutrition Examination Survey (NHANES) 1999–2014 cycles who were matched to participants from the National Heart, Lung and Blood Institute Pooled Cohort Study (NHLBI-PCS) for whom lifetime CVD risk factor trajectories (i.e., systolic BP [SBP], diastolic BP [DBP], high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, current smoker, former smoker, cigarettes per day, creatinine, estimated glomerular filtration rate, and diabetes mellitus) have been developed. Of these, individuals aged 20 years or older with suspected masked hypertension (i.e., mean of 3 SBP/DBP measurements 120–129 mm Hg/<80 mm Hg) with no history of CVD and no self-reported use of antihypertensive medications were included (n = 1,223). To achieve stable cost-effectiveness estimates, nationally representative cohorts of 100,000 US adults were simulated.

Screening strategies

We evaluated 3 strategies to diagnose and treat masked hypertension (Figure 1). The first was “usual care,” in which patients received annual screening for and treatment of hypertension using measured office BP per the 2017 ACC/AHA guidelines but did not receive any out-of-office BP screening. The second and third were “usual care plus ABPM” and “usual care plus HBPM,” in which patients received usual care plus screening for masked hypertension using either ABPM or HBPM, respectively. For masked hypertension screening, patients were rescreened every 3 years when aged <40 years and annually when aged ≥40 years.

Other screening intervals were evaluated in sensitivity analyses.

Model inputs

Blood pressure

The BP components included in the model are described in Table 1. The untreated “true” office BP represents an individual’s underlying office BP, without measurement error, had they not been treated with antihypertensive medication at any time in their life. It is derived from the NHLBI-PCS lifetime CVD risk factor trajectories. The “true” office BP is the treatment-adjusted office BP of an individual that applies the estimated BP reduction based on number of half- and full-standard dose medications used and adherence (Supplementary Table S1 online). To account for uncertainty in office BP measurements, error in BP measurements was incorporated as the difference between the measured office BP and the true office BP. All antihypertensive treatment was assumed to start with a half-standard dose and was subsequently titrated according to measured office BP.
As NHANES does not include out-of-office BP measurements, the validated Predicting Out-of-Office BP (PROOF-BP) algorithm, which uses office BP readings and patient characteristics, was used to estimate untreated out-of-office BP. We used sensitivity, specificity, and the out-of-office BP to determine clinical detection of a high out-of-office BP with ABPM and HBPM screening. In the primary analysis, ABPM was assumed to be the reference standard (100% sensitivity and 100% specificity). The diagnostic accuracy of HBPM was obtained from a meta-analysis comparing HBPM measurements with daytime ABPM measurements at a 130/80 mm Hg threshold (sensitivity 91.8% and specificity 41.4%) and accounted for typical use by patients at home. Similar to prior analyses, failure to obtain a complete ABP reading was set at 5% and required rescreening.

Risk of CVD events and non-CVD mortality The annual risk of first ever CVD event and non-CVD death was estimated using competing risks Cox proportional hazards functions derived from the NHLBI-PCS and operationalized using logistic regression (Supplementary Table S2 online). The probability of an incident CVD event each year was calculated using the untreated "true" office BP (Supplementary Methods online). In individuals with masked hypertension, an increased risk of CVD was estimated by pooling hazard ratios for masked hypertension vs. normotension from prior observational studies (HR = 1.77; Table 2 and Supplementary Table S3 online). There is limited evidence regarding the benefits of antihypertensive treatment for masked hypertension. Therefore, the relative risk per 10-mm Hg reduction in SBP from meta-analysis was applied to estimate the risk for CHD (RR = 0.83) and stroke (RR = 0.73) when using antihypertensive treatment. The probabilities for nonincident CVD events were stratified by age and sex (Supplementary Table S4 online).

Risk of medication-related adverse events Medication-related adverse events were classified as tolerable, intolerable (i.e., requiring discontinuation of antihypertensive medications), or serious (i.e., intolerable and requiring hospitalization). Serious adverse events had a risk of being fatal. As in prior analyses, the probabilities of each type of adverse event were associated with the number of full- and half-standard doses of antihypertensive medications used (Supplementary Methods online).

Costs The cost of masked hypertension screening included the cost of setup, education, device, and interpretation of results. The cost of an ABPM device was the average cost of ABPM devices listed on the CardiacDirect website at the time of the analysis (Supplementary Table S5 online). Each ABPM device was assumed to be purchased by physician offices and could be used by an average of 125 patients per year. The cost of an HBPM device was estimated by averaging the costs of the top 3 rated HBPM devices on Amazon at the time of the analysis. In the primary analysis, patients were assumed to purchase their own HBPM devices (i.e., the cost of 1 device per patient was included), but this was explored in a scenario analysis. The Centers for Medicare and Medicaid Services Physician fee schedule was used to define costs of physician visits associated with ABPM (CPT...
Table 1. Blood pressure variables included in the model

| Model blood pressure parameter | Definition | Source | Use in simulation |
|-------------------------------|------------|--------|------------------|
| Untreated “true” office BP    | Underlying office BP if no antihypertensive medications were ever used by patient | Projected trajectory over a lifetime using imputation analysis from NHANES and NHLBI Pooled Cohorts Study¹⁴,¹⁹–²¹ | Used to determine incident CVD event, CVD mortality, and serious adverse events were also included. In the primary analysis, the decrement to quality of life associated with medication pill-taking was 0.002.¹⁴,¹⁵ These assumptions were explored in scenario analyses. |
| Untreated out-of-office BP    | Underlying out-of-office BP if no antihypertensive medications were used | Obtained by applying PROOF-BP algorithm to the untreated “true” BP²⁵,²⁶ | Used with untreated “true” BP to determine “true” masked hypertension status |
| “True” office BP             | Office BP that accounts for antihypertensive medication use | Obtained by applying the expected BP reduction based on number of half- and full-standard dose medications used and adherence to regimen to the untreated “true” office BP¹⁴,²³ | Used to determine reduction in incident CVD event risk with antihypertensive medication treatment |
| Observed office BP           | BP seen in office by provider | Obtained by applying office BP measurement error to “true” office BP¹⁴,²⁴ | Used by provider to make antihypertensive medication treatment decisions |
| Observed out-of-office hypertension diagnosis | Out-of-office hypertension diagnosis by provider | Obtained by applying the accuracy (i.e., sensitivity and specificity) of ABPM and HBPM to “true” out-of-office BP²⁷ | Used by provider to make masked hypertension antihypertensive medication initiation decisions |

Abbreviations: ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CVD, cardiovascular disease; HBPM, home blood pressure monitoring; NHANES, National Health and Nutrition Examination Survey; NHLBI, National Heart, Lung and Blood Institute; PROOF-BP, PRedicting Out-of-OFfice Blood Pressure.

Quality of life We quantified health-related quality of life using quality-adjusted life years (QALYs), which range from one, indicating a year of full health, to zero, indicating death.¹⁶ The QALYs associated with chronic health states were age stratified and adjusted according to CVD history (Supplementary Table S6 online).¹⁵ Short-term QALY decrements after CVD events and serious adverse event hospitalizations were also included. In the primary analysis, the decrement to quality of life associated with medication pill-taking was 0.002.¹⁴,¹⁵ These assumptions were explored in scenario analyses.

Calibration and validation

As in prior analyses, the model was calibrated to match contemporary incidence and total event rates of CHD and stroke, and CVD and all-cause mortality from the Centers for Disease Control and Prevention, National Hospital Discharge Survey, National Inpatient Sample, and National Vital Statistics System, and cross-validated against the original, dynamic population version of the CVD Policy Model (Supplementary Methods and Figure S2 online).¹⁴–¹⁷

Statistical analysis

Our analysis adhered to recommendations from the Second Panel on Cost-effectiveness in Health and Medicine (Supplementary Tables S7 and S8 online).³⁶ The simulation model was developed and performed using TreeAge Pro (version 20.2.1, Williamstown, MA) and other analyses were performed in R (version 4.0.2, Vienna, Austria). The primary outcome was the incremental cost-effectiveness ratio (ICER), defined as the additional cost per QALY gained. Costs (2021 USD) were from a US healthcare sector perspective, which includes all direct medical costs regardless of the payer.³⁶ All future costs and QALYs were discounted 3% annually.³⁶ We used the cost-effectiveness thresholds recommended by the ACC/AHA, considering an ICER <$50,000/QALY gained highly cost-effective and an ICER ≥$50,000/QALY to <$150,000/QALY gained intermittently cost-effective.³⁷ For the primary analysis, 200 probabilistic iterations in which model inputs were randomly sampled from prespecified distributions were used to obtain the mean and 95% uncertainty interval (UI) for costs, QALYs, and the probability of being cost-effective. The rates of CVD events, CVD mortality, and serious adverse events were also projected.

Sensitivity and scenario analyses

One-way sensitivity analyses were performed by systematically varying model inputs related to masked hypertension across plausible ranges while holding all other parameters constant. The lower and upper bounds for the 1-way sensitivity analyses were derived from 95% confidence intervals or ranges reported in the literature. As the potential benefits and harms of treating masked
A 2-way sensitivity analysis assessed the joint impact of the probability of serious adverse events and the relative risk of CVD events per 10-mm Hg reduction in office BP with antihypertensive treatment on cost-effectiveness outcomes. Several scenario analyses were conducted to compare our approach to calculating the expected reduction in CVD event risk and quality of life to those used in prior cost-effectiveness studies (Supplementary Methods online).22,28,29 Finally, scenario analyses were performed in which (i) HBPM devices were purchased by physician offices and used by an average of 52 patients per year (i.e., the device cost was divided by 52 to calculate the cost per patient), (ii) HBPM had 100% sensitivity and specificity to detect masked hypertension, and (iii) ABPM had the same accuracy as HBPM (i.e., 91.8% sensitivity and 41.4% specificity).14,15

RESULTS

Participant characteristics

The simulated cohort was 43.3% female; 47.8% were non-Hispanic White and 19.5% non-Hispanic Black. The mean (SD) baseline age was 42.2 (14.8) years, body mass index was

### Table 2. Masked hypertension-related model inputs

| Parameter | Mean | Sensitivity analysis | Source |
|-----------|------|----------------------|--------|
| **Diagnostic accuracy of out-of-office BP screening** | | | |
| Sensitivity | | | |
| ABPM | 100.0% | 91.8%–100.0% | Ref. 27, ABPM lower bound assumed mean HBPM |
| HBPM | 91.8% | 84.4%–95.8% | |
| Specificity | | | |
| ABPM | 100.0% | 41.4%–100.0% | |
| HBPM | 41.4% | 30.1%–53.5% | |
| **Out-of-office BP rescreening interval** | | | |
| Age <40 years | Every 3 years | 1–5 | Ref. 22 |
| Age ≥40 years | Every year | 1–5 | Ref. 22 |
| **CVD risk with masked hypertension** | | | |
| Hazard ratio | 1.77 | 1.23–2.42 | Refs. 3–6 |
| **Costs** | | | |
| Usual care physician visit (per visit)a | $78 | $69–97 | CMS Physician fee scheduleb |
| Screening visit (cost per year) | | | CMS Physician fee scheduleb |
| ABPMc | $48 | $42–60 | |
| HBPMd | $28 | $23–34 | |
| **Device** | | | |
| ABPM | $1,916 | $1,495–2,195 | Mean of top devices from CardiacDirecte |
| HBPM | $54 | $45–63 | Mean of top devices from Amazonf |
| **Number of patients using device** | | | |
| ABPM | 125.0 | 62.5–187.5 | Ref. 28 |
| HBPM | 1 | 52 (purchased by clinics) | Clinical judgment |
| **ABPM failure rate** | 5.0% | 0.0%–10.0% | Ref. 22 |
| **Device replacement** | Every 5 years | 2–10 | Ref. 28, clinical judgment |
| **Quality-of-life** | | | |
| Pill-taking disutility | 0.002 | 0.000–0.006 | Refs. 14,15 |

**Abbreviations:** ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CMS, Center for Medicare and Medicaid Services; CVD, cardiovascular disease; HBPM, home blood pressure monitoring.

aCPT 99213.
bPhysician fee schedule: www.cms.gov/medicare/physician-fee-schedule/search.
cIncludes recording, scanning analysis, interpretation, and report (CPT 93784).
dIncludes initial setup, education (CPT code 99473), and interpretation of results (CPT 99474).
e24-Hour ABP Monitors: http://www.cardiacdirect.com/product-category/24-hour-abp-monitors.
fBest Sellers in Blood Pressure Monitors: www.amazon.com/Best-Sellers-Health-Personal-Care-Blood-Pressure-Monitors.
Clinical outcomes

Due to decreased specificity, screening for masked hypertension with HBPM was projected to result in more antihypertensive medications being started within the first year (68.3%) than usual care alone (0.0%) or usual care plus ABPM (28.5%). Screening for masked hypertension was projected to reduce the cumulative incidence of CVD events (Supplementary Figure S3 online). Compared with usual care alone, usual care plus ABPM screening decreased the CVD event rate by 14.3 (95% UI: 3.5–19.6) events per 100,000 person-years and usual care plus HBPM by 20.5 (95% UI: 11.9–26.8) events per 100,000 person-years (Table 3). The proportion of individuals who experienced a serious adverse event increased 2.7 percentage points with usual care plus ABPM (95% UI: 2.4–2.9) and 5.1 percentage points with usual care plus HBPM (95% UI: 4.6–5.7) relative to usual care.

Cost-effectiveness

Compared with usual care alone, usual care plus ABPM screening increased costs by an average $1,076 (95% UI: $945–1,206) per person over a lifetime and usual care plus HBPM by an average of $1,046 (95% UI: $928–1,187) per person (Table 4 and Supplementary Figure S4 online). Cost differences were driven by increased antihypertensive medication and antihypertensive related adverse events, which were partially offset by savings in CVD events prevented (Supplementary Table S9 online). Usual care plus ABPM gained 0.0126 (95% UI: 0.0019–0.0221) QALYs per person compared with usual care alone. Due to increased serious adverse events and pill-taking disutility, usual care plus HBPM lost 0.0021 (95% UI: −0.0163, 0.0109) QALYs compared with usual care alone. The resulting ICER for usual care plus ABPM vs. usual care alone was $85,164/QALY gained. Usual care plus HBPM was dominated by usual care alone (i.e., usual care plus HBPM was more costly and less effective). At a $150,000/QALY cost-effectiveness threshold, usual care plus ABPM had an 89.5% probability of being cost-effective (Table 4 and Figure 2).

Table 3. Lifetime CVD, survival, and adverse event projections

| Outcome (95% UI) | Usual care | Usual care plus ABPM | Usual care plus HBPM |
|------------------|------------|----------------------|----------------------|
| CVD (% with ≥1 event) | 25.6% (24.0%–26.9%) | 25.4% (23.7%–26.8%) | 25.1% (23.4%–26.8%) |
| CVD (total events per 100,000 person-years) | 1,057.7 (994.5–1,110.6) | 1,043.4 (979.0–1,101.5) | 1,037.2 (968.2–1,095.7) |
| Stroke (total events per 100,000 person-years) | 162.3 (154.1–169.3) | 156.6 (149.4–162.9) | 156.6 (149.4–162.5) |
| CHD (total events per 100,000 person-years) | 895.4 (837.5–949.4) | 886.8 (826.5–940.0) | 880.5 (817.8–935.3) |
| CVD death (total events per 100,000 person-years) | 336.3 (316.0–353.4) | 330.7 (309.3, 349.1) | 330.4 (308.5–348.9) |
| Survival (mean years) | 40.3 (40.2–40.4) | 40.3 (40.3–40.4) | 40.3 (40.3–40.4) |
| Serious adverse events (% with ≥1 event) | 20.5% (19.8%–21.0%) | 23.2% (22.3%–23.9%) | 25.6% (24.4%–26.7%) |
| Serious adverse events (per 100,000 person-years) | 589.5 (569.4–607.4) | 671.0 (643.8–697.2) | 750.8 (712.7–786.7) |

Table 4. Lifetime cost, effectiveness, and cost-effectiveness outcomes

| Outcomes | Usual care | Usual care plus ABPM | Usual care plus HBPM |
|----------|------------|----------------------|----------------------|
| Costs (2021 USD) | $199,899 | $200,975 | $200,945 |
| Incremental costs (95% UI) | — | $1,076 ($945–1,206) | $1,046 ($928–1,187) |
| QALYs | 18.6362 | 18.6499 | 18.6341 |
| Incremental QALYs (95% UI) | — | 0.0126 (0.0019–0.0221) | −0.0021 (−0.0164, 0.0109) |
| ICER (Inc. $/QALY gained) | — | $85,164 | Dominated |
| Probability preferred strategy at | | | |
| $50,000/QALY | 100.0% | 0.0% | 0.0% |
| $100,000/QALY | 34.0% | 66.0% | 0.0% |
| $150,000/QALY | 10.5% | 89.5% | 0.0% |

Abbreviations: ABPM, ambulatory blood pressure monitoring; CHD, coronary heart disease; CVD, cardiovascular disease; HBPM, home blood pressure monitoring; UI, uncertainty interval.

Cost-effectiveness

Compared with usual care alone, usual care plus ABPM screening increased costs by an average $1,076 (95% UI: $945–1,206) per person over a lifetime and usual care plus HBPM by an average of $1,046 (95% UI: $928–1,187) per person (Table 4 and Supplementary Figure S4 online). Cost differences were driven by increased antihypertensive medication and antihypertensive related adverse events, which were partially offset by savings in CVD events prevented (Supplementary Table S9 online). Usual care plus ABPM gained 0.0126 (95% UI: 0.0019–0.0221) QALYs per person compared with usual care alone. Due to increased serious adverse events and pill-taking disutility, usual care plus HBPM lost 0.0021 (95% UI: −0.0163, 0.0109) QALYs compared with usual care alone. The resulting ICER for usual care plus ABPM vs. usual care alone was $85,164/QALY gained. Usual care plus HBPM was dominated by usual care alone (i.e., usual care plus HBPM was more costly and less effective). At a $150,000/QALY cost-effectiveness threshold, usual care plus ABPM had an 89.5% probability of being cost-effective (Table 4 and Figure 2).
The cost-effectiveness of masked hypertension screening was most sensitive to changes in the specificity of ABPM, frequency of masked hypertension screening, and pill-taking disutility (Figure 3). The impact of simultaneous changes to the RR of CVD events and probability of treatment-related serious adverse events are shown in Supplementary Figure S5 online. Usual care plus ABPM was estimated to be highly cost-effective if the RR of CVD events was improved by 20%.

In the scenario analyses that used approaches from prior studies to calculate the expected reduction in CVD event risk and quality of life, a greater number of CVD events were prevented with masked hypertension screening using ABPM (31.1 per 100,000 person-years) and HBPM (43.9 per 100,000 person-years) than in the primary analysis (Supplementary Figure S6 online). Subsequently, usual care plus ABPM became highly cost-effective (ICER $30,269/QALY gained), but the results varied with pill-taking disutility (Supplementary Table S10 online). Assuming HBPM devices were purchased by physician offices and reused by patients had no impact on the cost-effectiveness of usual care plus HBPM (i.e., usual care plus HBPM remained dominated by usual care alone) (Supplementary Table S11 online). When HBPM was assumed to have 100% sensitivity and specificity, usual care plus HBPM dominated usual care plus ABPM and was cost-effective (ICER vs. usual care alone: $79,353/QALY gained). Usual care plus ABPM became dominated by usual care when the sensitivity and specificity were assumed to be the same as HBPM.

DISCUSSION

In this simulation study, we evaluated the cost-effectiveness of screening for and treating masked hypertension using either ABPM or HBPM in US adults with suspected masked hypertension. Both usual care plus ABPM and usual care plus HBPM screening strategies were projected to decrease CVD events and CVD-related mortality compared with usual care at lifetime incremental costs of screening near $1,000. Adding screening with ABPM to usual care was estimated to cost an average of $85,164/QALY gained over an individual’s lifetime compared with usual care. However, usual care plus HBPM resulted in lower QALYs than usual care due to increased treatment-related adverse events and pill-taking disutility and was not cost-effective. The cost-effectiveness of masked hypertension screening was most sensitive to the specificity of the screening strategy and the screening frequency.

The economic impact of out-of-office BP monitoring has been explored in previous studies, which have shown screening with ABPM to cost less and be more effective than not screening. However, these prior studies examined different populations and uses of ABPM compared with our study. Beyhaghi and Viera22 examined the use of ABPM for...
Masked Hypertension Screening Cost-Effectiveness

Figure 3. One-way sensitivity analyses of masked hypertension screening and treatment parameters, usual care plus ABPM vs. usual care alone. Notes: The figure shows the change in the ICER for usual care plus ABPM vs. usual care alone (x-axis) when independently varying the parameters shown (y-axis) across plausible ranges. The dashed line indicates the base-case ICER. At the ends of each bar, the parameter values that resulted in the maximum and minimum ICER are shown. The bars indicate if the parameter was associated with event probabilities/risk, ABPM measurement or procedures, or costs. Parameter values of screening frequency for masked hypertension are shown as aged <40 years/aged ≥40 years. Usual care alone dominated usual care plus ABPM (i.e., usual care cost less and was more effective) when the specificity of ABPM was 41.4% (same as HBPM), the screening frequency for masked hypertension was 5.00/5.00 years, and when pill-taking disutility was set to 0.006; the bars in the plot are cut off at $250,000/QALY gained for presentation. Usual care plus HBPM dominated usual care plus ABPM when pill-taking disutility was ≤0.001. Abbreviations: ABPM, ambulatory blood pressure monitoring; HBPM, home blood pressure monitoring; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.

adults aged 21 years and older in a US representative population, including those with high office BP. Lovibond et al. \(^{28}\) focused on use of ABPM in those with an office BP ≥140/90 mm Hg, and Monahan et al. \(^{29}\) on those with an office BP ≥130/80 mm Hg, aged 40 years and older. In contrast, we examined US adults aged 20 years and older without high office BP and with suspected masked hypertension (office BP 120–129/<80 mm Hg, no antihypertensive medication use, and no CVD history), many of whom may have a much lower risk of CVD than the populations studied in prior studies. Additionally, the prior studies used a different approach to estimating QALY reductions with CVD that generally results
in a greater quality of life benefit from CVD event prevention than our approach and used a greater CVD event-specific relative risk for individuals on antihypertensive medications than in our analysis. 22,28,29 When we adopted a similar approach, usual care plus ABPM became highly cost-effective (ICER $30,269/QALY gained). 28

Limitations

The results of our study need to be considered in the context of the following potential limitations. While the CVD Policy Model was calibrated to reproduce contemporary CVD event rates and mortality, it is a simulation model with a fixed set of assumptions about the underlying data and real-world clinical practice. Our primary analysis assumed the treatment benefits of antihypertensive medications were based on changes to office SBP and that individuals with masked hypertension receive the same treatment benefit per 10-mm Hg office SBP reduction as individuals with sustained hypertension. This assumption was based on the results from prior studies, but the treatment effect of antihypertensives on out-of-office BP and CVD risk in masked hypertension has not been assessed in any published randomized control trials. 22,28,29 These assumptions resulted in a modest CVD benefit in our model because office BP is lower in those with masked hypertension than those with sustained hypertension, and meta-analyses show higher starting BPs are associated with greater BP reductions with treatment. 30,31,38 Additionally, our analysis did not include the reduction in risk of heart failure associated with antihypertensive treatment. 9 Heart failure is associated with substantial morbidity, mortality, and healthcare costs; therefore, the benefits of antihypertensive treatment are likely underestimated in our analysis. 39,40 Another potential limitation of our study is the assumption that ABPM is the reference standard (100% sensitivity and specificity) for diagnosing masked hypertension. Recent literature suggests that, compared with 24-hour ABPM, mean BP measured by 1 week of HBPM is more reliable and strongly associated with left ventricular mass index, a reliable measure of end-organ damage. 41 When HBPM was assumed to have 100% sensitivity and specificity, usual care plus HBPM was projected to be the most cost-effective option (ICER: $79,353/QALY gained). Given this, and that the 2017 ACC/AHA BP guidelines state that HBPM or ABPM may be used to screen for masked hypertension, additional research is needed to better understand the ability of out-of-office screening to detect masked hypertension. Additionally, our analysis did not examine the impact of screening for masked hypertension within specific racial or ethnic groups. Future work is needed to ensure that screening for masked hypertension is equitable and reaches those at highest risk. Finally, while the PROOF-BP algorithm has been shown to accurately predict out-of-office BP, it may lead to some misclassification of participants.

In this simulation analysis, the addition of ABPM to usual care is estimated to reduce CVD morbidity and mortality and be an intermediate cost-effective way to screen for and treat masked hypertension in US adults suspected to have masked hypertension.

SUPPLEMENTARY MATERIAL

Supplementary data are available at American Journal of Hypertension online.

FUNDING

Dr Shimbo was supported by K24H125704 and R01HL139716 from the National Heart, Lung, and Blood Institute (NHLBI) (Bethesda, MD). Drs Moran, Shimbo, Zhang, Shea, and Bellows were supported by R01HL130500 from the NHLBI (Bethesda, MD). Dr Bress was supported by K01HL133468 from the National Heart, Lung, and Blood Institute (NHLBI) (Bethesda, MD). Dr Sheppard receives funding from the Wellcome Trust/Royal Society via a Sir Henry Dale Fellowship (ref: 211182/Z/18/Z). Drs Sheppard and McManus receive funding from the National Institute for Health Research (NIHR) School for Primary Care Research, NIHR Oxford Biomedical Research Centre, NIHR ARC Oxford and Thames Valley, British Heart Foundation, and Stroke Association. Dr McManus is an NIHR Senior Investigator. Dr Bellows was supported by K01HL140170 from the NHLBI (Bethesda, MD). This research was funded in part, by the Wellcome Trust (211182/Z/18/Z). For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.

DISCLOSURE

Dr McManus has received consulting and licensing fees paid to his institution from Omron Healthcare. The remaining authors have no relevant disclosures to declare.

This manuscript was sent to Guest Editor, Hillel W. Cohen, MPH, DrPH for editorial handling and final disposition.

REFERENCES

1. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamarson KA, Jones DW, MacLaughlin EJ, Muntner P, Oskiachele B, Smith SC Jr, Spencer CC, Stafford RS, Talor SJ, Thomas RJ, Williams K, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018; 138:e426–e483.
2. Wang YC, Shimbo D, Muntner P, Moran AE, Krakoff LR, Schwartz JE. Prevalence of masked hypertension among us adults with nonelevated clinic blood pressure. Am J Epidemiol 2017; 185:194–202.
3. Asayama K, Thijs L, Brguljan-Hitij J, Niiranen TJ, Hozawa A, Boggia J, Aparicio LS, Har A, Johansson JK, Ohtubu T, Tsuzuki C, Stergiou GS, Sandoya E, Tsuji I, Jula AM, Imai Y, Staessen JA; International Database of Home Blood Pressure in Relation to Cardiovascular Outcome (IDHOCO) investigators. Risk stratification by self-measured home blood pressure across categories of conventional blood pressure: a participant-level meta-analysis. PLoS Med 2014; 11:e1001591.
4. Asayama K, Thijs L, Li Y, Gu YM, Hara A, Liu YP, Zhang Z, Wei FF, Lujambio I, Mena LJ, Boggia J, Hansen TW, Borklund-Bodegard K, Nomura K, Ohkubo T, Jeppesen J, Torp-Pedersen C, Dolan E, Stolarz-Skrzypek K, Malyutina S, Casiglia E, Nikitin Y, Lind L, Luzardo L, Kawecka-Jaszcz K, Sandøya E, Filipovsky J, Maestre GE, Wang J, Imai Y, Franklin SS, O’Brien E, Staessen JA; International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators. Setting thresholds to varying blood pressure monitoring intervals differentially affects risk estimates associated with white-coat and masked hypertension in the population. *Hypertension* 2014; 64:935–942.

5. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially uncontrolled subjects: an updated meta-analysis. *Am J Hypertens* 2011; 24:52–58.

6. Stergios GS, Asayama K, Thijs L, Kollias A, Niiranen TJ, Hozawa A, Boggia J, Johansson JK, Ohkubo T, Tsuji I, Jula AM, Imai Y, Staessen JA; International Database on Home blood pressure in relation to Cardiovascular Outcome. *Hypertension* 2014; 63:675–682.

7. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement D, Coca A, De Simone G, Dominiczak A, Kahan T, Mahouf F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen S, Kreutz R, Laurent S, Lip GYH, McM anus R, Narkiewicz K, Ruschitzka F, Sitges-Ruiz R, Shlyakhto E, Tsouftsa K, Abiyans Y, Desormais I; List of authors/Task Force members. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology:ESH/ESC Task Force for the management of arterial hypertension. *J Hypertens* 2018; 36:2284–2309.

8. Anstey DE, Pugliese D, Abdalla M, Bello NA, Givens R, Shimbo D. Rationale for ambulatory and home blood pressure monitoring compared with ambulatory blood pressure monitoring thresholds in the 2017 American College of Cardiology/American Heart Association guideline. *Hypertension* 2019; 73:33–38.

9. Anstey DE, Bradley C, Shimbo D. USPSTF Recommendation statement on hypertension screening in adults—where do we go from here? *JAMA Netw Open* 2021; 4:e214203.

10. Krist AH, Davidson KW, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Duben CA, Kubik M, Li L, Ogedegbe G, Phillips SK, Silverstein M, Stewerner J, Tseng CW, Wong J, Zeltzer L. Preventive Services Task Force. Screening for hypertension in adults: US preventive services task force reaffirmation recommendation statement. *JAMA* 2021; 325:1650–1656.

11. Siu AL; U S Preventive Services Task Force. Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2015; 163:861–868.

12. Bryant KB, Moran AE, Kazi DS, Zhang Y, Penko J, Ruiz-Negrón N, Coxson P, Blyler CA, Lynch K, Cohen LP, Tajee GS, Fontil V, Moy NB, Ebinger JE, Rader F, Bibbins-Domingo K, Bellows BK. Cost-effectiveness of hypertension treatment by pharmacists in black barbershops. *Circulation* 2021; 143:2384–2394.

13. Kohli-Lynch CN, Bellows BK, Thanassoulis G, Zhang Y, Fletcher MJ, Vittinghoff E, Pencina MJ, Kazi D, Sniderman AD, Moran AE. Cost-effectiveness of low-density lipoprotein cholesterol level-guided statin treatment in patients with borderline cardiovascular risk. *JAMA Cardiol* 2019; 4:969–977.

14. Moran AE, Odden MC, Thanataveerat A, Tzong KY, Rasmussen PW, Guzman D, Williams L, Bibbins-Domingo K, Coxson PG, Goldman L. Cost-effectiveness of hypertension therapy according to 2014 guidelines. *N Engl J Med* 2015; 372:326–327.

15. Weinstei n MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. *Am J Public Health* 1987; 77:1417–1426.

16. Cohen LP, Vittinghoff E, Fletcher MJ, Allen NB, Shah SJ, Wilkins JT, Chang PP, Nduamele CE, Newman AB, Ives D, Maurer MS, Oelsner EC, Moran AE, Zhang Y. Association of midlife cardiovascular risk factors with the risk of heart failure subtypes later in life. *J Card Fail* 2021; 27:435–444.

17. Oelsner EC, Balte PP, Cassano PA, Couper D, Enright PL, Folsom AR, Hankinson J, Jacobs DR Jr, Kallhun R, Kaplan R, Kronmal R, Lange L, Loehr LR, London SJ, Navas Acien A, Newman AB, O’Connor GT, Schwartz JE, Smith LJ, Yeh F, Zhang Y, Moran AE, Movassoglu S, White WB, Yende S, Barr RG. Harmonization of respiratory data from 9 US population-based cohorts: the NHLBI Pooled Cohorts Study. *Am J Epidemiol* 2018; 187:2265–2278.

18. Zeki Al Hazzouri A, Vittinghoff E, Zhang Y, Fletcher MJ, Moran AE, Bibbins-Domingo K, Golden SH, Yaffe K. Use of a pooled cohort to impute cardiovascular disease risk factors across the adult life course. *Int J Epidemiol* 2019; 48:1004–1013.

19. Moy NB, Ebinger JE, Rader F, Bibbins-Domingo K, Bellows BK. Impact of self-monitoring of blood pressure on processes of hypertension care and long-term blood pressure control. *J Am Heart Assoc* 2020; 9:e016174.

20. Monahan M, Jowett S, Lovibond K, Gill P, Godwin M, Greenfield S, King JB, Pletcher MJ, Bibbins-Domingo K, Moran AE, McManus RJ, Bellows BK. Cost-effectiveness of hypertension treatment by pharmacists in black barbershops. *Ann Intern Med* 2021; 174:841–850.

21. Hanley J, Hobbs FR, Mant J, McKinstry B, Myers M, Nunan D, Ward A, Williams B, McManus RJ. Predicting Out-of-Office Blood Pressure in the Clinic (PROOF-BP): derivation and validation of a tool to improve the accuracy of blood pressure measurement in clinical practice. *Hypertension* 2016; 67:941–950.

22. Sheppard JP, Martin U, Gill P, Stevens R, Hobbs FR, Mant J, Godwin M, Hanley J, Heneghan C, Hobs FD, Mant J, McKinistry B, Myers M, Nunan D, Ward A, Williams B, McManus RJ. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in hypertension: systematic review. *BMJ* 2011; 343:d3621.

23. Lovibond K, Jowett S, Barton P, Caulfield M, Heneghan C, Hobs FD, Hodgkinson J, Mant J, Martin U, Guo B, Hobs FD, Deeks JJ, Hendrier C, Roberts N, McManus RJ. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in hypertension: systematic review. *BMJ* 2013; 346:f1001.

24. Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. *Health Technol Assess* 2003; 7:1–94.

25. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 35 randomised trials. *BMJ* 2003; 326:127.

26. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Cheung AK, Muntner P, Carey RM, Jamerson K, Wright JT Jr, Whelton PK. Rationale for ambulatory and home blood pressure monitoring thresholds in the 2017 American College of Cardiology/American Heart Association guideline. *Hypertension* 2018; 64:935–942.

27. Anstey DE, Bradley C, Shimbo D. USPSTF Recommendation statement on hypertension screening in adults—where do we go from here? *JAMA Netw Open* 2021; 4:e214203.
33. Xie X, Atkins E, Ly J, Bennett A, Neal B, Ninomiya T, Woodward M, MacMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahimi K, Perkovic V, Rodgers A. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. *Lancet* 2016; 387:435–443.

34. Hodgkinson JA, Lee MM, Milner S, Bradburn P, Stevens R, Hobbs FR, Koshiaris C, Grant S, Mant J, McManus RJ. Accuracy of blood-pressure monitors owned by patients with hypertension (ACCU-RATE study): a cross-sectional, observational study in central England. *Br J Gen Pract* 2020; 70:e548–e554.

35. Gold MR, Stevenson D, Fryback DG. HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population health. *Annu Rev Public Health* 2002; 23:115–134.

36. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpter MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. *JAMA* 2016; 316:1093–1103.

37. Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ, Halperin JL, Hatlky MA, Jacobs AK, Mark DB, Masoudi FA, Peterson ED, Shaw LJ. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on performance measures and task force on practice guidelines. *J Am Coll Cardiol* 2014; 63:2304–2322.

38. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ* 2009; 338:b1665.

39. Urbich M, Globe G, Pantiri K, Hiese M, Bennison C, Wirtz HS, Di Tanna GL. A systematic review of medical costs associated with heart failure in the USA (2014–2020). *PharmacoEconomics* 2020; 38:1219–1236.

40. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Elkind MSV, Ewenson KR, Ferguson JE, Gupta DK, Khan SS, Kissela BM, Knutson KL, Lee CD, Lewis TT, Liu J, Loop MS, Latsey PL, Ma J, Mackey J, Martin SS, Matchar DB, Mussolino ME, Navaneethan SD, Perak AM, Roth GA, Samad Z, Sato GM, Schroeder EB, Shah SH, Shay CM, Stokes A, VanWagner LB, Wang NY, Tsao CW; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2021 update: a report from the American Heart Association. *Circulation* 2021; 143:e254–e743.

41. Schwartz JE, Muntnner P, Kronish IM, Burg MM, Pickering TG, Bigger JT, Shimbo D. Reliability of office, home, and ambulatory blood pressure measurements and correlation with left ventricular mass. *J Am Coll Cardiol* 2020; 76:2911–2922.